Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of the Efficacy,Safety and Quality of Life After TOOKAD Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Prostate Cancer

Next Previous
Trial Profile

Study of the Efficacy,Safety and Quality of Life After TOOKAD Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Prostate Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Padeliporfin (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Steba Biotech

    • Most Recent Events

    • 03 Feb 2016 New trial record
    • 01 Feb 2016 Top-line results published in a Steba Biotech media release.
    • 01 Feb 2016 On the basis of positive results from this trial, Steba Biotech has submitted a marketing authorization application for TOOKAD (padeliporfin) to the Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS), the Mexican health authority. After review, the COFEPRIS has granted the first marketing authorization for TOOKAD for the treatment of low-risk localized prostate cancer patients on November 12, 2015
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top